Measuring Inflammation and Oxidative Stress Markers in Gaucher Disease
Studies inflammation and oxidative stress markers in adults with Gaucher disease.
Plain-language title generated from the registry record
Registry title: Oxidative Stress and Inflammatory Biomarkers in Gaucher Disease
Key facts
- Where
- Minneapolis, United StatesSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT02437396, who can take part
Where in United States
- University of MinnesotaMinneapolis, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Minnesota
- Trial code
- NCT02437396
- Record updated
- 4 November 2026
- Original description
The objective of this study is to evaluate oxidative stress and/or inflammation in patients with Gaucher disease type I using a series of biomarkers and correlate with measurements of currently used diagnostic biomarkers.Read full original descriptionShow less
Novel Inflammatory Biomarkers Complement 5A and Hepcidin in Patients With Gaucher Disease (GD)
The objective of this study is to evaluate oxidative stress and/or inflammation in patients with Gaucher disease type I using a series of biomarkers and correlate with measurements of currently used diagnostic biomarkers.
Inclusion: All participants must be 18 years or older; All enrollees must understand and cooperate with requirements of the study in the opinion of the investigators and must be able to provide written informed consent; Individuals with Gaucher disease who are medically stable for participation in study in the opinion of the investigator; GD subjects must be stable on a specific ERT and/or SRT therapy at a specific dose (for e.g. on a units/kg basis) for at least 2 years or be naïve to these therapies (no therapy for 2 years); GD1 patients, who have had a change in therapy i.e. a change in dose or switch from one drug to another, can be enrolled after at least 6 months have elapsed since the change and is considered stable in the opinion of the clinician providing care to the patient; All participants must not have taken antioxidants coenzyme Q-10, vitamin C, or vitamin E for 3 weeks prior to the study.
Exclusion: Concurrent disease; medical condition; or an extenuating circumstance that, in the opinion of the investigator, might compromise subject safety, study compliance, completion of the study, or the integrity of the data collected for the study; Medically unstable conditions in any group as determined by the investigators; History of asthma that is presently being treated; Females who are pregnant or lactating or of child-bearing age who are not using acceptable forms of contraception; Subjects who cannot or are unwilling to have blood drawn; Unable to adhere to study protocol for whatever reason.